The PHD inhibitor FG4592 (Roxadustat) is routinely used in vitro as an experimental tool to stabilize HIF1α (Jain et al, 2016) and was under FDA evaluation for anemia treatment (https://clinicaltrials.gov/ct2/show/NCT01750190; Guenzler‐Pukall et al, 2003; Rabinowitz, 2013; Joharapurkar et al, 2018). This evidence concerns the gene HIF1A and anemia (phenotype).